These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 19666153)

  • 1. The chimerical multi-component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection.
    Carcelén J; Iniesta V; Fernández-Cotrina J; Serrano F; Parejo JC; Corraliza I; Gallardo-Soler A; Marañón F; Soto M; Alonso C; Gómez-Nieto C
    Vaccine; 2009 Oct; 27(43):5964-73. PubMed ID: 19666153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection.
    Ramos I; Alonso A; Peris A; Marcen JM; Abengozar MA; Alcolea PJ; Castillo JA; Larraga V
    Vaccine; 2009 Nov; 27(48):6695-703. PubMed ID: 19747996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG + Q mix protects Balb/c mice from infection.
    Parody N; Soto M; Requena JM; Alonso C
    Parasite Immunol; 2004; 26(6-7):283-93. PubMed ID: 15541032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants.
    Poot J; Janssen LH; van Kasteren-Westerneng TJ; van der Heijden-Liefkens KH; Schijns VE; Heckeroth A
    Vaccine; 2009 Jul; 27(33):4439-46. PubMed ID: 19500553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
    Rodríguez-Cortés A; Ojeda A; López-Fuertes L; Timón M; Altet L; Solano-Gallego L; Sánchez-Robert E; Francino O; Alberola J
    Vaccine; 2007 Nov; 25(46):7962-71. PubMed ID: 17942199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gentamicin-attenuated Leishmania infantum: a clinicopathological study in dogs.
    Daneshvar H; Molaei MM; Afshar RM; Kamiabi H; Burchmore R; Hagan P; Phillips RS
    Vet Immunol Immunopathol; 2009 May; 129(1-2):28-35. PubMed ID: 19147233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
    Lemesre JL; Holzmuller P; Cavaleyra M; Gonçalves RB; Hottin G; Papierok G
    Vaccine; 2005 Apr; 23(22):2825-40. PubMed ID: 15780731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.
    Gradoni L; Foglia Manzillo V; Pagano A; Piantedosi D; De Luna R; Gramiccia M; Scalone A; Di Muccio T; Oliva G
    Vaccine; 2005 Nov; 23(45):5245-51. PubMed ID: 16054272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.
    Petitdidier E; Pagniez J; Papierok G; Vincendeau P; Lemesre JL; Bras-Gonçalves R
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004614. PubMed ID: 27223609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gentamicin-attenuated Leishmania infantum: cellular immunity production and protection of dogs against experimental canine leishmaniasis.
    Daneshvar H; Molaei MM; Kamiabi H; Burchmore R; Hagan P; Stephen Phillips R
    Parasite Immunol; 2010; 32(11-12):722-30. PubMed ID: 21039612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
    Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
    Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
    Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
    Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum.
    Bras-Gonçalves R; Petitdidier E; Pagniez J; Veyrier R; Cibrelus P; Cavaleyra M; Maquaire S; Moreaux J; Lemesre JL
    Infect Genet Evol; 2014 Jun; 24():1-14. PubMed ID: 24614507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
    Khoshgoo N; Zahedifard F; Azizi H; Taslimi Y; Alonso MJ; Rafati S
    Vaccine; 2008 Oct; 26(46):5822-9. PubMed ID: 18804512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.
    Rafati S; Nakhaee A; Taheri T; Taslimi Y; Darabi H; Eravani D; Sanos S; Kaye P; Taghikhani M; Jamshidi S; Rad MA
    Vaccine; 2005 May; 23(28):3716-25. PubMed ID: 15882533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective humoral and cellular immunoprotective responses in Li ESAp-MDP vaccinated protected dogs.
    Bourdoiseau G; Hugnet C; Gonçalves RB; Vézilier F; Petit-Didier E; Papierok G; Lemesre JL
    Vet Immunol Immunopathol; 2009 Mar; 128(1-3):71-8. PubMed ID: 19046774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection of appropriate serological tests to measure the incidence of natural Leishmania infantum infection during DNA/MVA prime/boost canine vaccine trials.
    Carson C; Antoniou M; Christodoulou V; Messaritakis I; Quinnell RJ; Blackwell JM; Courtenay O
    Vet Parasitol; 2009 Jun; 162(3-4):207-13. PubMed ID: 19386420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A long term experimental study of canine visceral leishmaniasis.
    Rodríguez-Cortés A; Ojeda A; López-Fuertes L; Timón M; Altet L; Solano-Gallego L; Sánchez-Robert E; Francino O; Alberola J
    Int J Parasitol; 2007 May; 37(6):683-93. PubMed ID: 17239885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canine Leishmania vaccines: still a long way to go.
    Gradoni L
    Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.